In this study, we demonstrated that ganetespib (STA-9090), a non-benzoquinone ansamycin Hsp90 inhibitor specifically targeting ATP-binding domain, significantly attenuated the development of the disease in mice with AD induced by topical application of DNCB. Here, HSP90AB1 is linked to Alzheimer disease.